Skip to Main Content
Skip Nav Destination

Selenium compounds, in both inorganic and organic forms have been explored for development as radioprotectors, agents used to minimize the deleterious effects of radiation. Most of the research in this direction has been focused on inorganic selenium, including several clinical studies where selenium supplementation yielded useful outcomes in cancer patients undergoing radiotherapy. Since organic selenium is less toxic than inorganic selenium, researchers are now focusing on the development of organoselenium compounds for radioprotection. Both natural and synthetic organoselenium compounds are being examined and one such water-soluble selenium compound, 3,3′-diselenodipropionic acid (DSePA) developed by our group, showed promising activity at pre-clinical stages. These results, along with the current status and future scope of research, are discussed in this chapter.

You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal